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We investigated host-derived biomarkers that were previously identified in QuantiFERON 
supernatants, in a large pan-African study. We recruited individuals presenting with symptoms of 
pulmonary TB at seven peripheral healthcare facilities in six African countries, prior to assessment 
for TB disease. We then evaluated the concentrations of 12 biomarkers in stored QuantiFERON 
supernatants using the Luminex platform. Based on laboratory, clinical and radiological findings and a 
pre-established algorithm, participants were classified as TB disease or other respiratory diseases(ORD). 
Of the 514 individuals included in the study, 179(34.8%) had TB disease, 274(51.5%) had ORD and 
61(11.5%) had an uncertain diagnosis. A biosignature comprising unstimulated IFN-γ, MIP-1β, TGF-α 
and antigen-specific levels of TGF-α and VEGF, identified on a training sample set (n = 311), validated 
by diagnosing TB disease in the test set (n = 134) with an AUC of 0.81(95% CI, 0.76–0.86), corresponding 
to a sensitivity of 64.2%(95% CI, 49.7–76.5%) and specificity of 82.7%(95% CI, 72.4–89.9%). Host 
biomarkers detected in QuantiFERON supernatants can contribute to the diagnosis of active TB disease 
amongst people presenting with symptoms requiring investigation for TB disease, regardless of HIV 
status or ethnicity in Africa.
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Tuberculosis (TB) remains a global health problem, with an estimated 10.4 million new TB patients and 1.4 mil-
lion deaths due to TB, reported in 20151. The most widely used diagnostic test for TB especially in resource-poor 
settings (sputum smear microscopy) has poor sensitivity, whereas the gold standard test (culture) has a long 
turnaround time (up to 42 days), is expensive, prone to contamination and requires extensive laboratory infra-
structure2. The GeneXpert MTB/RIF test, arguably the most important recent advance in TB diagnostics, yields 
results within 2 hours and detects resistance to rifampicin as a proxy for MDR-TB diagnosis. However, despite 
the extensive roll out of the GeneXpert, cost effectiveness and the requirement for technical infrastructure limits 
its use in resource-poor settings. As a consequence, the test is mostly offered in centralized facilities with ade-
quate laboratory infrastructure. In addition, an important limitation of tests based on sputum, including the 
GeneXpert, is their unsuitability for individuals with difficulty in providing sputum specimens and those with 
paucibacillary disease such as children3, HIV infected individuals and patients with extra-pulmonary TB4. Assays 
employing the detection of host inflammatory biosignatures may be beneficial, as they have shown promise for 
development as rapid point-of-care tests for both pulmonary and extrapulmonary TB5–8.
The tuberculin skin test (TST) and interferon gamma (IFN-γ) release assays (IGRAs) remain the most widely 
used and recommended immunological tests for the diagnosis of Mycobacterium tuberculosis (Mtb) infection9. 
However, these assays are not very useful in the diagnosis of active TB disease9,10. Moreover, they can be falsely 
negative in advanced TB cases, most likely due to T cell anergy5,11. Several investigations have shown the diag-
nostic potential of host markers other than IFN-γ, which can be detected in QuantiFERON supernatants in 
diagnosing TB disease12–15. In addition, investigations into the discovery of alternative infection-phase dependent 
antigens other than those used in IGRAs (ESAT-6/CFP-10/TB7.7; present in the QuantiFERON In Tube assay), 
have been attempted16–20.
We have previously shown a 3-marker host biosignature consisting of epidermal growth factor (EGF), mac-
rophage inflammatory protein (MIP)-1β and interleukin (IL)-1α, which resulted in the correct classification of 
87% of adult pulmonary TB cases and 91% of household contacts after cross validation following QuantiFERON 
stimulation of whole blood12. However, this requires validation in a larger cohort of TB cases, including HIV posi-
tive and HIV negative subjects, from different geographical regions. Therefore, the aim of the present study was to 
validate the diagnostic potential of the 3-marker biosignature together with promising markers identified in other 
studies for the diagnosis of TB disease amongst individuals with symptoms suggestive of TB from six African 
countries (Ethiopia, Gambia, Malawi, Namibia, South Africa and Uganda), irrespective of HIV co-infection.
Results
Study subjects. Samples from 514 study participants were evaluated (Fig. 1). Using the pre-established TB 
classification algorithm described in21, 160 (31.1%) of the study participants were definite pulmonary TB patients, 
19 (3.7%) were probable TB patients, 274 (53.5%) were individuals with other respiratory diseases (ORDs), 
whereas 61(11.9%) of study participants had questionable disease status (Table 1). There was no significant differ-
ence between the proportion of patients with TB disease or ORD that were HIV infected (Chi-Square, p = 0.08) 
or between males and females with TB or ORD across sites (Chi-square, p = 0.16). The proportion of individuals 
presenting with symptoms requiring investigation for TB and who were finally diagnosed with TB disease was 
not the same across the different study sites (Table 1, Chi-square p < 0.01), with the TB patients slightly younger 
than those with ORD (35.7 ± 12.6 Vs. 36.8 ± 13.2; Chi-square p < 0.01, Table 1).
Diagnostic potential of individual host markers for TB disease. We compared all individuals diag-
nosed with TB disease (definite and probable TB; n = 179) to those with ORD (n = 274) for both unstimulated 
(N) and TB antigen induced values (Ag-N) responses for each individual marker; obtained by subtraction of the 
unstimulated (nil) from the antigen stimulated (Ag) responses, regardless of HIV infection status. These values 
were considered separate variables during statistical analysis in order to evaluate the contribution of each to 
diagnostic biosignatures.
Significant differences were observed for the unstimulated and/or antigen specific levels of eight mark-
ers (Table 2). The median unstimulated levels of VEGF, IFN-γ, sCD40L, TGF-α, IFN-α2 and MMP-9, and 
antigen-specific levels of IL-1ra, IFN-γ, TGF-α and MMP-9 were significantly higher in the TB patients whereas 
the unstimulated levels of MIP-1β and IL-1α were significantly higher in individuals with ORD (Table 2).
When analysis was performed only in HIV uninfected individuals (135 TB Vs. 223 ORD), significant differ-
ences were observed for unstimulated levels of IL-1ra, VEGF, IFN-γ, IFN-α2, sCD40L, MIP-1β, TGF-α, MMP-2, 
MMP-9, and antigen-specific levels of IL-1ra, VEGF, IFN-γ, TGF-α and MMP-9 (see Supplementary Table S1). 
When only the definite TB cases (n = 160) were compared to all the ORDs, regardless of HIV infection status, 
significant differences were observed for the unstimulated levels of VEGF, IFN-γ, IFN-α2, sCD40L, MIP-1β, 
TGF-α, MMP-9 and the antigen-specific levels of TGF-α, IFN-γ, VEGF and IL-1ra (see Supplementary Table S2).
When the diagnostic accuracies of individual host markers were ascertained by ROC curve analysis, unstimu-
lated IFN-γ was the only marker that showed diagnostic potential, with area under the ROC curve (AUC) of 0.72 
(95% CI, 0.67–0.78) in all study participants, regardless of HIV status (Table 2), and also in HIV negative indi-
viduals only (AUC = 0.73; 95% CI, 0.68–0.78) (see Supplementary Table S1). When only the definite TB patients 
were compared to ORD, the AUCs for individual analytes ranged from 0.52 (95% CI, 0.45–0.60) for unstimulated 
IL-1ra, to 0.75(95% CI, 0.70–0.80) for unstimulated IFN-γ (see Supplementary Table S2), thereby confirming the 
limited utility of individual analytes, and also suggesting that Mtb antigen stimulation might not be necessary for 
optimal diagnosis of TB disease.
Utility of the previous 3-marker EGF, MIP-1β and IL-1α signature in the diagnosis of TB disease. 
We evaluated the accuracy of the 3-marker (EGF, MIP-1β and IL-1α) biosignature identified in our previous 
small, case-control study12 in the present study. When evaluated on all study participants (regardless of HIV 
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infection status), the 3-marker signature only diagnosed TB disease in the training sample set (70% of all study 
participants), with a sensitivity of 68.9% and specificity of 52.9%. In the test set (the remaining 30% of study 
participants) the sensitivity and specificity of the 3-marker model were 60.4% and 58.0% respectively. When 
evaluated in HIV negative participants only, the sensitivity and specificity of the 3-marker model (54.8% and 
59.2% respectively) were equally poor in the test sample set, with similar results (although with higher specificity) 
obtained in the HIV positive individuals (sensitivity of 40% and specificity of 90% in the test set).
Diagnostic Potential of other multi-marker biosignatures for TB disease. We next evaluated the 
predictive abilities of combinations between different host markers using general discriminant analysis (GDA). 
As not all host markers were evaluated at all study sites (IL-1ra and IFN-α2 were not evaluated on KPS, MRCG, 
and UCRC samples and TNF-α was not evaluated on MRCG samples), the GDA was performed twice: -we first 
evaluated diagnostic biosignatures in patients for whom all host markers had been evaluated. Secondly, we evalu-
ated combinations between host markers that had been evaluated at all study sites (i.e. excluding IL-1ra, IFN-α2 
and TNF-α), regardless of HIV infection status, or study site. Optimal prediction of TB disease Vs. ORD was 
achieved when markers were used in combinations of four.
When all host markers were analysed for available sites (n = 251), a four-marker signature comprising unstim-
ulated IFN-γ, unstimulated TGF-α and antigen-specific levels of IL-1ra and MIP-1β diagnosed TB disease with 
a sensitivity of 70.7% (95% CI, 58.9–80.3%), and specificity of 81.2% (95% CI, 71.9–88.0%) in the training set 
(n = 176; 75 TB and 101 ORDs), and a sensitivity of 68.8% (95% CI, 50.0–83.3%) and specificity of 76.7% (95% 
CI, 61.0–87.7%) in the test sample set (n = 75; n = 32 TB and n = 43 ORD). The positive and negative predictive 
values of the biosignature in the test set were 68.8% (95% CI, 50.0–83.3%) and 76.7% (95% CI, 61.0–87.7%), 
respectively.
When analysis was performed only on the host markers that were evaluated in all study participants, opti-
mal prediction of TB disease was achieved when markers were used in combinations of five. The most accurate 
five-marker biosignature, comprised unstimulated levels of IFN-γ, MIP-1β and TGF-α and antigen-specific levels 
of TGF-α and VEGF, and diagnosed TB disease in the training sample set (n = 311; n = 122 TB, n = 189 ORD) 
with sensitivity of 68.9% (95% CI, 59.7–76.8%) and specificity of 83.1% (95% CI, 76.8–88.0%), and a sensitivity 
of 64.2% (95% CI, 49.7–76.5%) and specificity of 82.7% (95% CI, 72.4–89.9%) in the test set (n = 134; n = 53 TB 
Figure 1. STARD flow diagram showing the study design and classification of study participants. CRF, case 
report form; TB, Pulmonary tuberculosis; ORD, Individuals presenting with symptoms and investigated for 
pulmonary TB but in whom TB disease was ruled out; ROC, Receiver operator characteristics; GDA, General 
discriminant analysis.
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and n = 81 ORD). The positive and negative predictive values of the five-marker biosignature in the test set were 
70.8% (95% CI, 55.7–82.6%) and 77.9% (95% CI, 67.4–85.9%), respectively (Fig. 2, Table 3).
After optimization of biosignatures by selection of cut-off levels that would yield the best possible combi-
nations of sensitivity and specificity, for possible future development of a screening test, the sensitivity of the 
four-marker biosignature in the test set increased to 81.3%, at the expense of lower specificity (56.0%, AUC = 0.79, 
95%CI, 0.72–0.86), whereas the sensitivity of the five-marker model on all study participants (limited analytes) 
increased slightly to 77.4% with the specificity reducing to 60.5%, in the test set (AUC = 0.81, 95%CI, 0.76–0.86).
Accuracy of biosignatures in HIV negative subjects. To investigate whether the accuracy of the bio-
marker combinations was influenced by HIV infection, we stratified the study participants according to HIV 
status and repeated the GDA in the HIV uninfected participants. For analysis of all analytes where available, a 
seven-marker biosignature comprising unstimulated levels of IFN-γ, IFN-α2, sCD40L, IL-1α, MMP-2, MMP-9 
and antigen-specific IFN-α2 diagnosed TB disease with a sensitivity of 81.2% (95% CI 66.9–90.6%) and specific-
ity of 81.2% (95% CI, 70.9–88.5%) in the training sample set (n = 133; n = 48 TB, n = 85 ORD), and a sensitivity 
of 50.0% (95% CI 27.9–72.1%), and specificity of 83.3% (95% CI 66.5–93.0%) in the test set (n = 56; n = 20 TB 
and n = 36 ORD). The positive and negative predictive values of the biosignature in the test set were 62.5% (95% 
CI, 35.9–83.7%) and 75.0% (95% CI, 58.5–86.8%) respectively. When the analysis was done only on the host 
markers that were evaluated at all study sites, a seven-marker combination comprising unstimulated levels of 
IFN-γ, TGF-α, IL-1a, MMP-2 and the antigen-specific levels of EGF, VEGF and TGF-α diagnosed TB disease 
with a sensitivity of 73.9% (95%CI, 63.5–82.3%) and specificity of 84.5% (95% CI 77.6–89.6%) in the training set 
(n = 247; n = 92TB, n = 155 ORD), and a sensitivity of 51.3% (95% CI 35.0–67.3% and specificity of 77.3% (95% 
CI, 65.0–86.3%) in the test set (n = 105; n = 39 TB, n = 66 ORD). The positive and negative predictive values of 
the biosignature in the test set were 57.1% (95% CI, 39.5–73.2%) and 72.9% (95% CI, 60.7–82.4%), respectively. 
Attempts to optimize the biosignature by selection of better cut-off values resulted in a sensitivity and specificity 
Study site SUN AHRI KPS MRCG UCRC EHNRI UNAM Total
Participants (n) 75 76 76 72 67 73 75 514
Age, mean ± SD 38.6 ± 10.7 30.9 ± 12.6 38.6 ± 14.7 35.1 ± 13.4 32.5 ± 10.6 37.5 ± 14.1 36.2 ± 9.5 35.7 ± 12.6
Males, n(%) 35(47) 40(53) 39(51) 55(76) 42(63) 33(45) 39(52) 283(55)
HIV pos, n(%) 11(15) 11(14) 37(49) 0(0) 1(1) 18(25) 44(59) 122(24)
QFT pos, n(%) 48(66) 46(61) 25(33) 38(53) 54(81) 36(49) 40(53) 287(56)
*Definite, n(%) 20(27) 30(39) 6(8) 34(47) 24(36) 18(25) 28(37) 160(31)
$Probable, n(%) 0(0) 2(3) 5(7) 0(0) 2(3) 1(1) 9(12) 19(4)
£ORD, n (%) 46(61) 44 (58) 55(72) 35(49) 38(57) 39(53) 17(23) 274(53.3)
Questionable, n(%) 9(12) 0(0) 10(13) 3(4) 3(4) 15(21) 21(28) 61(11.9)
TB cases♯ (n) 20 32 11 34 26 19 37 179(34.2)
Age, mean ± SD 38.2 ± 9.2 28.7 ± 13.6 34.5 ± 13.2 31.5 ± 11.7 33.1 ± 9.5 27.9 ± 9.7 34.6 ± 9.5 35.7 ± 12.6
Males, n(%) 8(40) 16(50) 5(45) 30(88) 16(62) 11(58) 20(54) 106(59)
HIV pos, n(%) 4(20) 7(22) 4(36) 0(0) 1(4) 5(26) 23(62) 44(25)
QFT pos, n(%) 14(74) 26(81) 7(64) 26(76) 25(96) 12(63) 23(62) 133(75)
QFT neg, n(%) 4(21) 6(19) 4(36) 8(24) 1(4) 6(32) 11(30) 40(22)
QFT Indet., n(%) 1(5) 0(0) 0(0) 0(0) 0(0) 1(5) 3(8) 5(3)
ORD 45 44 55 35 38 39 17 274(53.3)
Age, mean ± SD 38.2 ± 11.2 32.4 ± 11.7 39.4 ± 15.5 39.3 ± 14.3 31.7 ± 11.0 38.6 ± 13.5 37.5 ± 10.6 36.8 ± 13.2
Males, n(%) 21(47) 24(55) 30(55) 22(63) 24(63) 14(36) 6(35) 141(51)
HIV pos, n(%) 6(13) 4(9) 26(47) 0(0) 0(0) 6(15) 9(53) 51(19)
QFT pos, n(%) 28(62) 20(45) 16(29) 11(31) 26(68) 20(51) 10(59) 131(48)
QFT neg, n(%) 17(3) 22(50) 33(60) 24(69) 11(29) 19(49) 7(41) 133(49)
QFT Indet., n(%) 0(0) 2(5) 6(11) 0(0) 1(3) 0(0) 0(0) 9(3)
Table 1. Clinical and demographic characteristics of study participants. *As previously described in21, 
participants were classified as Definite TB patients if MTB was isolated from their sputum samples by culture 
and/or when they had two positive smears and their symptoms responded well to treatment and/or if they 
had a single positive smear (only one smear done) and their chest X-rays were suggestive of pulmonary TB. 
$Participants were classified as probable TB if they had one positive sputum smear (in the absence of a culture 
result) and their symptoms responded well to TB treatment, or when they had very suggestive chest X-rays 
and their symptoms responded to TB treatment. £Participants were classified as ORD if they had negative 
cultures, negative smears, and negative chest X-rays and treatment was never initiated by healthcare providers. 
QuantiFERON results (positive, negative or indeterminate) were obtained using the software provided by 
the manufacturer. Abbreviations: SUN = Stellenbosch University, South Africa; AHRI = Armauer Hansen 
Research Institute, Ethiopia; KPS = Karonga Prevention Study, Malawi, MRC = Medical Research Council Unit, 
The Gambia, UCRC = Makerere University, Uganda; EHNRI = Ethiopian Public Health Institute, Ethiopia; 
UNAM = University of Namibia, Namibia; SD = standard deviation; QFT = QuantiFERON TB Gold In Tube; 
pos = positive; neg = negative; indet = indeterminate. ♯TB cases = Definite TB + probable TB cases.
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of both 67% in the test sample set. The frequency of host markers in the most accurate prediction models for the 
diagnosis of TB in the absence of HIV infection is shown in Fig. 3.
Utility of bisignatures in the diagnosis of smear positive and smear negative TB. Given that 
smear microscopy remains the most widely used test in resource poor settings, we evaluated the utility of the 
biosignatures identified in this study (Table 3) in the diagnosis of TB disease in smear positive and smear negative 
TB patients, regardless of the HIV infection status of study participants. The AUCs for all the four different bio-
signatures ranged from 0.81 (95% CI, 0.73–0.90) to 0.83 (95% CI, 0.77–0.88) for the diagnosis of smear positive 
TB disease, and from 0.70 (95% CI, 0.60–0.79) to 0.74 (95% CI, 0.63–0.84) for the diagnosis of smear negative 
TB (Table 4). The most accurate biosignature for the diagnosis of smear positive TB (IFN-γN, TGF-αN, IL-1αN, 
MMP-2N, EGFAg-N, VEGFAg-N and TGF-α Ag-N) performed in this study group with a sensitivity of 75.7% (28/37) 
and specificity of 80% (52/65) in the test set, whereas the most accurate biosignature for the diagnosis of smear 
negative TB (IFN-γN, IFN-αN, sCD40LN, IL-1αN, MMP-2N, MMP-9N and IFN-α2Ag-N) performed with a sensitiv-
ity of 60% (24/40) and specificity of 70.8% (102/144).
Discussion
The development of rapid, accurate, inexpensive and sputum independent TB diagnostic tools, that are suita-
ble for use in high burden but resource-constrained settings, remains an important priority in the fight against 
TB22. Ideally, such tools should yield results within 20 minutes22 and based on easily obtainable samples such 
as serum, urine or other ex vivo bodily fluids8. In the absence of such tools, overnight antigen-stimulated tests, 
employing simple detection platforms such as lateral flow technology might be beneficial, provided that they are 
accurate, inexpensive and require minimal infrastructure23. In the present study, we evaluated the usefulness of 
host biomarkers detected in overnight whole blood culture (QuantiFERON) supernatants as potential diagnostic 
markers for TB disease in a large, multi-center trial, involving seven field sites, situated in six African countries. 
The concentrations of IL-1ra, IFN-α2, VEGF, sCD40L, MIP-1β, MMP-9, TGF-α and IFN-γ with or without anti-
gen (ESAT/CFP-10/TB7.7) stimulation discriminated between TB patients and individuals with ORD. Although 
unstimulated IFN-γ levels showed promise, no single marker was sufficiently discriminatory as a stand-alone 
diagnostic marker for active TB. A previous 3-marker signature (EGF, MIP-1β and IL-1α)12 did not validate in the 
present multi-site study. However, four- and five-marker biosignatures comprising unstimulated levels of IFN-γ, 
MIP-1β and TGF-α, and the antigen-specific levels of TGF-α, VEGF, IL-1ra and MIP-1β diagnosed TB disease 
with sensitivity up to 81.3% and specificity up to 82.7%, regardless of HIV infection status, depending on which 
biomarkers were used in combination but specificity was generally low when biosignatures were optimized for 
high sensitivity. The most accurate four-marker biosignature comprising of the unistimulated levels of IFN-γ and 
TGF-α and the antigen specific levels of IL-1Ra and MIP-1β diagnosed TB disease in all study participants with a 
sensitivity of 81.3% and a specificity of 56.0%.
Although there are many stages in the Mtb infection/disease spectrum24, rapid discrimination between indi-
viduals who are infected with Mtb as evidenced by T cell reactivity to Mtb antigens, from those with active TB 
disease and for whom treatment is urgently needed, remains an important question. This is especially the case in 
the usually resource-constrained but high burden settings, with high prevalences of LTBI and poor diagnostic 
facilities. The development of IGRAs remains the most important recent advance in the development of immu-
nodiagnostic tests for TB. However, it is widely known that IGRAs do not discriminate between active TB disease 
and LTBI, and IGRA responses have a poor predictive value as they do not correlate with any of the stages in the 
Mtb infection/disease spectrum9. In an attempt to identify alternative T-cell based diagnostic approaches, differ-
ent researchers have investigated several alternative antigens to ESAT-6/CFP-1016,25,26 and more relevant to the 
Analyte TB (IQR) ORD (IQR) P-value AUC (95% CI) Cut-off Sens (95% CI) Spec (95% CI)
IL-1raAg-N 124.1(26.4–486) 78.7(0–361.1) 0.032 0.58 (0.51–0.65) >90.3 0.60 (0.50–0.69) 0.52(0.43–0.60)
VEGFN 102.2(0.0–213) 40.7(0.0–118.5) <0.001 0.63(0.58–0.68) >74.8 0.60 (0.53–0.68) 0.60(0.54–0.65)
IFN-γN 17.6(7.7–36) 5.6(1.1–14.0) <0.001 0.72(0.67–0.77) >8.7 0.73(0.66–0.78) 0.63(0.57–0.68)
IFN-γAg-N 115.8(21.5–340) 23.1(0.8–169.3) <0.001 0.64(0.59–0.69) >46.5 0.67 (0.60–0.74) 0.60 (0.54–0.66)
IFN-α2N 35.9(14.6–55) 20.0(7.7–39.6) 0.001 0.62(0.55–0.69) >24.9 0.62(0.52–0.71) 0.58(0.49–0.66)
sCD40LN 2322.8(1197.4–4507) 1344.4(765.6–2611.2) <0.01 0.63(0.58–0.69) >1717 0.63(0.55–0.70) 0.60(0.54–0.66)
MIP-1βN 752.6(386.8–1673) 1289.1(651.2–2466.0) <0.01 0.63(0.58–0.68) <1164 0.62(0.54–0.69) 0.54 (0.49–0.61)
MIP-1βA-N 467.5(19.6–1160) 627.9(22.6–2013.8) 0.05 0.55(0.50–0.60) <705.6 0.63(0.55–0.69) 0.49(0.43–0.55)
IL-1αN 9.1(0.5–29) 14.2(3.1–52.5) 0.017 0.50(0.45–0.56) <4.8 0.55(0.47–0.62) 0.51(0.44–0.56)
TGF-αN 18.0(11.2–30) 9.8(4.2–19.1) <0.001 0.68(0.63–0.73) >12.9 0.71(0.64–0.78) 0.60(0.54–0.66)
TGF-αA-N 0.9(−1.8–6.0) 0.0(−1.8–2.9) 0.021 0.56(0.51–0.62) >0.6 0.53(0.456–0.60) 0.60(0.54–0.66)
MMP-9N 809798.8(455045.7–1275200) 508208.0(298946.4–865698.0) <0.001 0.66(0.60–0.71) >618289 0.60(0.52–0.68) 0.61(0.55–0.67)
MMP-9Ag-N 36703.4(−40408–234300) 4119.5(−82800–113700) 0.005 0.58(0.52–0.64 >3578 0.59(0.50–0.67) 0.50(0.44–0.56)
Table 2. Median levels of individual analytes (pg/ml) in TB patients (n = 179) and individuals with ORD 
(n = 274) and accuracies in the diagnosis of TB disease. Only analytes with p-values < 0.05 in the Mann 
Whitney U test are shown. IQR = Inter-quartile range, AUC = area under the ROC curve, Sens = sensitivity, 
spec = specificity N = Unistimulated levels, Ag-N = antigen specific levels.
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current study, alternative host markers other than IFN-γ, detected after stimulation with ESAT-6/CFP-10/TB7.7 
in QuantiFERON tubes, as reviewed in18. While different host biomarker signatures have been shown to be poten-
tially useful, most of the work reported so far has been in small, single-site case-control studies and mostly in HIV 
uninfected individuals. Comparisons between these different, relatively small studies, is difficult, due to the high 
variability in both the types of patients, and the host markers investigated. Given the heterogeneity in immune 
responses against Mtb antigens across different populations18, it is imperative that any promising immunological 
assays be evaluated in large, multi-site studies, to ascertain the possible global applicability of the findings. As 
far as we are aware, our study is the first attempt to accomplish this. We therefore aimed to further elucidate the 
diagnostic potential of the most promising host markers so far identified in QuantiFERON supernatants, in a 
relatively large, highly diverse Pan-African cohort of patients that presented with signs and symptoms requiring 
investigation for pulmonary TB. Our objective was to refine and validate these biosignatures, and to identify a 
biosignature that could potentially be incorporated into easy-to-perform test platforms such as lateral flow based 
systems, which were recently investigated in different African countries8,23.
Our finding that four- to five-marker biosignatures detected in QuantiFERON supernatants have potential in 
the diagnosis of TB disease regardless of HIV infection status in this relatively large, multi-center study, attests 
to the promising nature of possible future tests based on such biosignatures. Although the performance of these 
biosignatures might be sub-optimal when compared to recent serum and plasma-based studies21,27, a diagnostic 
test based on these biosignatures expectedly has value in the difficult to diagnose TB cases, especially if optimized 
for high sensitivity, to enable the use of such biosignatures as screening tools for active TB disease. The markers 
need to be incorporated into an inexpensive and easily performed test system applicable in resource constrained 
Figure 2. Accuracy of multi-marker models in the diagnosis of TB disease. Receiver operator characteristics 
(ROC) curve showing the accuracy of the most accurate four-marker biosignature (IFN-γnil + TGF-αnil + IL-
1raAg-nil + MIP-1βAg-nil) in the diagnosis of TB disease regardless of HIV infection status when all host markers 
evaluated were considered (251 study participants) (A), frequency of analytes in the top 20 general discriminant 
analysis (GDA) models that most accurately classified study participants as TB disease or ORD irrespective of 
HIV status when all host markers evaluated were considered (B), ROC curve showing the accuracy of the most 
accurate five-marker biosignature (IFN-γnil + MIP-1βnil + TGF-αnil + TGF-αAg-nil + VEGFAg-nil) in the diagnosis 
of TB disease regardless of HIV status when analysis was done only on the host markers that were evaluated 
on all study participants (i.e., excluding IL-1ra, IFN-α2 and TNF-α) (C), and frequency of analytes in the top 
20 GDA models that most accurately diagnosed TB disease regardless of HIV status when analysis was done 
only on the host markers that were evaluated on all study participants (D). The bar graphs (B,D) indicate the 
frequency of analytes in the most accurate GDA models.
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settings. Optimization of threshold values for the biosignatures, to accurately determine how the markers could 
be used in potential rule-in or rule-out tests is ongoing. However, biosignatures such as those investigated in 
the current study may not be useful alone, and may have to be combined with other clinical and laboratory 
parameters.
Regarding the possible use of the biosignatures in the field, the recently published FIND/WHO target product 
profiles (TPPs) recommend that a non-sputum based biomarker test performs with an overall sensitivity ≥80% 
in adults, an optimal sensitivity ≥98% in the diagnosis of smear positive/culture positive TB and ≥68% for smear 
negative/culture positive TB, and with an optimal specificity ≥98% against a microbiological reference stand-
ard22. The most accurate biosignatures identified in the current study; with a sensitivity of 75.7% and specificity 
of 80% in the diagnosis of smear positive TB, and a sensitivity of 60% and specificity of 70.8% in the diagnosis of 
smear negative TB in the test set, performed sub-optimally when considering the FIND/WHO TPPs. However, 
as observed when the biosignatures were evaluated in all study participants regardless of HIV infection status, 
selection of better cut-off values yielded the desired optimal sensitivities (≥98%) with all the different biosigna-
tures, but this was usually at the expense of lower specificity (data not shown). More work is currently being done 
to further optimise these biosignatures, including the improvement of the signatures by addition of more recently 
identified promising host markers.
Recently we developed field-friendly assays utilizing the lateral flow (LF) format in combination with upcon-
verting phosphor (UCP) technology that allows quantitative detection of multiple biomarkers directly in culture 
supernatants28,29. For field-friendly use, the concentrations of analytes could be determined using a hand-held 
LF strip scanner, allowing point-of-care screening in remote settings (where culture and GeneXpert facilities are 
absent). Prototypes of UCP-LF tests, are currently being investigated within our consortium8,23. In the context of 
the current study, the levels of the biomarkers may be measured directly in the Quantiferon tubes after stimula-
tion with antigens using the lateral flow test, without the need for ELISAs as it is currently done in IGRAs. The 
importance of discriminating between TB and ORD when patients present with similar symptoms to primary 
healthcare facilities often without even X-ray facilities cannot be overstated. Considering all patients in this study 
had some form of respiratory infection resulting in non-specific inflammatory responses in the lungs, the fact that 
we could identify biosignatures with up to 83% specificity for TB holds promise for future development of rapid 
screening tests for TB22. It will be important to further investigate these signatures in difficult-to-diagnose TB 
cases such as childhood TB and extrapulmonary TB cases in future studies. Furthermore, as discussed in another 
study21, it will be important if future studies include individuals with firmly established alternative diagnoses as 
the ORD group in the current study was not worked-up for confirmation of alternative diseases as patients were 
recruited at primary healthcare settings where diagnostic tools to confirm such alternative diagnoses are lacking. 
As the study participants included in the present study were patients presenting at primary health care facilities 
with symptoms and then investigated for TB disease, individuals with HIV infection were not investigated further 
for the purposes of staging with CD4 counts and viral loads. Furthermore, data on antiretroviral therapy was 
not collected as our interest was in the performance of biomarkers in patients with TB symptoms, regardless of 
whether they were HIV infected or not. It is therefore not certain how severe HIV infection might influence the 
accuracies of the biosignatures and that needs to be investigated in future studies.
Biosignature(i) obtained when all host markers (n = 12) were considered; implying limited numbers of study participants (N = 251), from 4 sites only, regardless of HIV status
Training set (N = 176, n = 75 TB, n = 101 ORD) Test set (n = 75, n = 32TB; n = 43ORD)
Biosignature (i)a Sensitivity Specificity Sensitivity Specificity PPV NPV
IFN-γN, TGF-αN, IL-1RaAg-N, MIP-
1βAg-N
70.7% (58.9–80.3) 81.2% (71.9–88.0) 68.8%(50.0–83.3) 76.7%(61.0–87.7) 68.8%(50.0–83.3) 76.7%(61.0–87.7)
Biosignature (ii) obtained when all study participants (n = 445*, all sites) were considered, implying limited numbers of markers (n = 9)
Biosignature (ii) Training set (n = 311; n = 122 TB, n = 189 ORD) Test set (N = 134; n = 53 TB; n = 81 ORD)
IFN-γN, MIP-1βN, TGF-αN, TGF-αAg-N, 
VEGFAg-N
68.9%(59.7–76.5) 83.1%(76.8–88.0) c64.2%(49.7–76.5) d82.7%(72.4–89.9) 70.8%(55.7–82.6) 77.9%(67.4–85.9)
Biosignature (iii) obtained when all host markers (n = 12) were considered in HIV negative study participants only; implying limited numbers of study participants (N = 189), 
from 4 study sites
Biosignature (iii) Training set: N = 133; n = 48 TB, n = 85 ORD Test set: N = 56; n = 20 TB, n = 36 ORD
IFN-γN, IFN-αN, sCD40LN, IL-1αN, 
MMP-2N, MMP-9N, IFN-α2Ag-N
81.2%(66.9–90.6) 81.2%(70.9–88.5) 50.0%(27.9–72.1) 83.3%(66.5–93.0) 62.5%(35.9–83.7) 75.0(58.8–86.8)
Biosignature (iv) obtained when all HIV negative participants (n = 352*, all sites) were considered, implying limited numbers of markers (n = 9)
Biosignature (iv) Training set (N = 247; n = 92 TB, n = 155 ORD) Test set (n = 105; n = 39 TB, n = 66 ORD)
IFN-γN, TGF-αN, IL-1αN, MMP-2N, 
EGFAg-N, VEGFAg-N, TGF-α Ag-N
73.9%(63.5–82.3) 84.5%(77.6–89.6) 51.3%(35.0–67.3) 77.3%(65.0–86.3) 57.1%(39.5–73.2) 72.9%(60.7–82.4)
Table 3. Summary of diagnosticc biosignatures identified in this study. All host markers were not evaluated 
at all study sites: IL-1ra and IFN-α2 were not evaluated on KPS, MRCG, and UCRC samples, whereas TNF-α 
was additionally not evaluated on MRCG samples for technical reasons. The GDA modelling procedure 
was therefore performed twice. *Individuals with questionable TB status (see Table 1) were excluded. aThe 
sensitivity of biosignature (i) increased to 81.3% and specificity decreased to 56.0% when the biosignature was 
optimized for high sensitivity. bThe sensitivity of biosignature (ii) increased to77.4% and specificity decreased to 
60.5% when the biosignature was optimized for high sensitivity. N = Unstimulated (nil) value, Ag-N = antigen-
specific response obtained after subtraction of nil from antigen-stimulated value.
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In conclusion, the current study demonstrates that host biosignatures including four or five analytes obtained 
from Mtb-antigen stimulated or non-stimulated, overnight whole blood culture supernatants may be useful for 
the diagnosis of TB disease, in patients presenting with symptoms that are similar to TB, regardless of HIV infec-
tion status or ethnicity in Africa. Implementation of host biosignatures in low-complexity screening tools, as 
our previously described UCP-LF assay platform for cyto-/chemokine detection, may be beneficial in situations 
where sputum-based microbiological tests are not feasible.
Figure 3. Accuracy of multi-marker models in the diagnosis of TB disease in the absence of HIV infection. 
Frequency of analytes in the top 20 general discriminant analysis (GDA) models that most accurately classified 
study participants regardless of HIV infection status, when all host markers evaluated were considered (limited 
numbers of study participants) (A), frequency of analytes in the top 20 GDA models that most accurately 
classified study participants as TB disease or ORD irrespective of HIV status when all study participants (limited 
numbers of host markers) were considered (B), ROC curve showing the accuracy of the most accurate seven-
marker biosignature (IFN-γN, TGF-αN, IL-1αN, MMP-2N, EGFAg-N, VEGFAg-N, TGF-α Ag-N) in the diagnosis of 
TB disease regardless of HIV status when analysis was done only on the host markers that were evaluated on all 
study participants (i.e., excluding IL-1ra, IFN-α2 and TNF-α) (C). The bar graphs (A,B) indicate the frequency 
of analytes in the top 20 most accurate GDA models.
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Methods
Study participants. We prospectively recruited adults who presented with symptoms requiring investiga-
tion for pulmonary TB disease at primary health care clinics at seven field sites, situated in six African countries. 
As previously reported19,21, the clinics served as field study sites for researchers at Stellenbosch University (SUN), 
South Africa; Makerere University (UCRC), Uganda; Medical Research Council Unit The Gambia (MRCG); 
Karonga Prevention Study (KPS), Malawi; the University of Namibia (UNAM), Namibia, Armaur Hansen 
Research Institute (AHRI), Ethiopia; the Ethiopian Public Health Institute (EHNRI), Ethiopia. Study participants 
were recruited between November 2010 and November 2012.
As described previously8,19,21,27,30, study participants presented with persistent cough lasting ≥2 weeks and at 
least one of either fever, malaise, recent weight loss, night sweats, knowledge of close contact with a confirmed TB 
patient, haemoptysis, chest pain or loss of appetite. Participants were eligible for the study if they were 18 years or 
older and willing to give written informed consent, including consent for HIV testing. Patients were excluded if 
they were pregnant, had not been residing in the study community for more than 3 months, were severely anae-
mic (haemoglobin <10 g/l), had concurrent malaria infection (The Gambia), were on anti-TB treatment, received 
anti-TB treatment in the previous 90 days or if they received quinolone or aminoglycoside antibiotics during the 
past 60 days. At enrolment, case report forms were completed for all study participants and sputum and blood 
samples collected for analysis as described below. Harmonized clinical and laboratory protocols were used across 
the study sites. All study procedures were conducted according to the Declaration of Helsinki. The study protocol 
was approved by the Health Research Ethics Committees of all the participating institutions.
Sample collection and diagnostic tests. Whole blood was collected directly into QuantiFERON TB 
Gold In Tube tubes (1 ml per tube) as recommended by the manufacturer (Qiagen, Germany). The tubes were 
transported at ambient conditions to the respective laboratories and incubated overnight (18 to 22 hours) at 37 °C, 
5% CO2. Tubes were then centrifuged at 2,500 g for 15 minutes and supernatants harvested, aliquoted and frozen 
(−80 °C) until use.
Sputum samples were cultured either using the MGIT method (BD Biosciences) or on Lowenstein Jensen 
media, depending on the facilities at each site. Specimens demonstrating growth of microorganisms were exam-
ined for acid-fast bacilli using the Ziehl-Neelsen method, followed by either Capilia TB testing (TAUNS, Numazu, 
Japan) or standard biochemical methods, to confirm the isolation of organisms of the Mtb complex, before being 
designated as positive cultures.
Classification of study participants and reference standard. As described previously19,21,27, study 
participants were classified as either definite TB patients, probable TB patients, participants with other respira-
tory diseases (ORD) or questionable disease status, using a combination of clinical, radiological, and laboratory 
findings. As previously reported21,27, individuals with ORDs had a range of other diagnoses, including upper and 
lower respiratory tract infections (viral and bacterial infections), and acute exacerbations of chronic obstructive 
pulmonary disease or asthma. However, attempts to identify any other organisms by bacterial or viral cultures 
were not made.
A total of 1,384 individuals (25.7% of whom were HIV infected) were enrolled at all sites during the study 
period. However, the current investigation only involved 514 individuals (24%, n = 122 HIV positive) that were 
recruited during the first half of the project, consistently using the same inclusion criteria. In assessing the accu-
racy of host biosignatures in the diagnosis of TB disease, all definite and probable TB cases were classified as “TB”, 
and then compared to participants with ORDs, whereas questionables were excluded from the main analysis 
(Fig. 1).
Biosignature Accuracy measure
Accuracy in smear Positive TB patients Accuracy in Smear Negative TB Patients
Training set Test set Training set Test set
Biosignature (i) AUC 0.82 (0.75–0.90) 0.70 (0.61–0.79)
IFN-γN, TGF-αN, IL-1RaAg-N, MIP-1βAg-N
Sensitivity 72.3% (34/47) 80.0% (16/20) 60% (24/40) 57.5% (23/40)
Specificity 85.1% (86/101) 79.5% (35/44) 73.1% (106/145) 71.0% (103/145)
Biosignature (ii) AUC 0.82 (0.77–0.88) 0.70 (0.60–0.79)
IFN-γN, MIP-1βN, TGF-αN, TGF-αAg-N, VEGFAg-N
Sensitivity 71.8% (61/85) 56.8% (21/37) 57.8% (26/45) 55.6% (25/45)
Specificity 83.7% (128/153) 90.8% (59/65) 75.2% (164/218) 72.9% (159/218)
Biosignature (iii) AUC 0.81 (0.73–0.90) 0.74 (0.63–0.84)
IFN-γN, IFN-αN, sCD40LN, IL-1αN, MMP-2N, MMP-9N, IFN-α2Ag-N
Sensitivity 73.9% (34/46) 75.0% (15/20) 65% (26/40) 60% (24/40)
Specificity 82.2% (83/101) 90.7% (39/43) 72.9% (105/144) 70.8% (102/144)
Biosignature (iv) AUC 0.83 (0.77–0.88) 0.70 (0.60–0.79)
IFN-γN, TGF-αN, IL-1αN, MMP-2N, EGFAg-N, VEGFAg-N, TGF-α Ag-N
Sensitivity 70.6% (60/85) 75.7% (28/37) 57.8% (26/45) 55.6% (25/45)
Specificity 85.0% (130/153) 80.0% (52/65) 75.2% (164/218) 72.9% (159/218)
Table 4. Performance of host biosignatures in smear positive and smear negative TB patients regardless of 
HIV infection status. Cut-off values for determination of sensitivity and specificity were selected based on the 
Younden’s Index.
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Immunoassays. IFN-γ concentrations in QuantiFERON supernatants were determined using the 
QuantiFERON TB Gold ELISA kit and the results interpreted for Mtb infection using the analysis software pro-
vided by the manufacturer (Qiagen, Germany). QuantiFERON results were only used to determine the Mtb 
infection status of study participants and not for clinical management of patients.
The concentrations of the previously identified three markers (EGF, MIP-1β, IL-1α), as well as those of nine 
other markers that have shown potential including soluble CD40 ligand (sCD40L), transforming growth factor 
(TGF)-α, vascular endothelial growth factor (VEGF), IFN-α2, interleukin-1 receptor antagonist (IL-1ra), tumour 
necrosis factor (TNF)-α, IFN-γ, matrix metalloproteinase (MMP)-2 and MMP-9, were evaluated in aliquots of 
the unstimulated (nil) and M.tb antigen-stimulated QuantiFERON supernatants from each participant using 
customized Milliplex Luminex kits (Merck Millipore, Billerica, MA, USA), on the Bio Plex platform (Bio Rad 
Laboratories, Hercules, CA, USA). QuantiFERON mitogen control supernatants were not evaluated as they did 
not contribute to diagnostic biosignatures in previous studies12. All samples were evaluated blinded to the clinical 
classification and QuantiFERON status of study participants. The Bio Plex manager software, version 6.1 (Bio Rad 
Laboratories), was used for bead acquisition and analysis of median fluorescence intensity.
Statistical analysis. Differences in the concentrations of host markers between the individuals with TB 
disease and those with ORDs were determined using the Mann–Whitney U test. The diagnostic accuracy for indi-
vidual markers was ascertained by receiver operator characteristics (ROC) curve analysis. Optimal cut-off values 
and associated sensitivity and specificity were selected based on the Youden’s index31. The predictive abilities of 
combinations of analytes were investigated by performing best subsets general discriminant analysis (GDA)31,32, 
following the training/test set approach. Briefly, participants were randomly assigned into a training sample set 
(70%) or test set (30%), regardless of HIV infection status and biosignatures identified on the training set were 
validated on the test set. These training and test sets were selected using random sampling, stratified on the 
dependent (TB) variable. The data were analysed using Statistica (Statsoft, Ohio, USA) and Prism (Graph Pad 
Prism, San Diego, CA, USA).
Availability of materials and data. The data presented in the current manuscript are available upon 
request from Gerhard Walzl or Novel N Chegou.
Ethical approval and informed consent. All study procedures were conducted according to the 
Declaration of Helsinki. The study protocol was approved by the Health Research Ethics Committees of all the 
participating institutions.
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